Novo Nordisk Trades at 10 Times Earnings While Buying Back Billions in Stock. Is This the Bottom?

Impact · against what's priced in

The article provides no actionable catalyst for Eli Lilly, as its market dominance and the threat of Novo Nordisk's oral GLP-1 are already factored into its valuation. For Novo Nordisk, the shift to a volume-driven model and the buyback program provide a potential floor, though the current valuation already reflects a massive collapse in multiple.

LLY+0.00

Already priced in

The price assumes

Current GLP-1 market dominance